Reviewing Nanosphere (NSPH) and Its Peers

Nanosphere (NASDAQ: NSPH) is one of 78 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its competitors? We will compare Nanosphere to related businesses based on the strength of its earnings, institutional ownership, profitability, dividends, valuation, analyst recommendations and risk.

Analyst Recommendations

This is a summary of current ratings for Nanosphere and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nanosphere 0 0 0 0 N/A
Nanosphere Competitors 333 1989 3500 112 2.57

As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 4.73%. Given Nanosphere’s competitors higher probable upside, analysts clearly believe Nanosphere has less favorable growth aspects than its competitors.

Profitability

This table compares Nanosphere and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nanosphere -99.68% -232.37% -65.52%
Nanosphere Competitors -153.79% -22.72% -9.21%

Insider and Institutional Ownership

52.3% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 18.0% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Nanosphere and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Nanosphere N/A N/A -0.31
Nanosphere Competitors $2.19 billion $239.22 million -63.05

Nanosphere’s competitors have higher revenue and earnings than Nanosphere. Nanosphere is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Nanosphere competitors beat Nanosphere on 6 of the 8 factors compared.

About Nanosphere

Nanosphere, Inc. is engaged in developing, manufacturing and marketing an advanced molecular diagnostics platform, the Verigene System, which enables genomic and protein testing on a single platform. The Verigene System includes a molecular diagnostics workstation that is a single use consumable for testing. The Verigene System consists of a microfluidics processor, a touchscreen reader and disposable test cartridges. The Company is focused on the infectious disease diagnostics market. Its Infectious Disease Assays include Respiratory Virus with Sub-Typing (RV+); Respiratory Pathogens/Expanded Panel (RP Flex); Bloodstream Infection (BSI) Panels, which include Blood Culture – Gram Positive (BC-GP), Blood Culture – Gram Negative (BC-GN) and Blood Culture – Yeast (BC-Y); C. difficile (CDF), and Enteric Panel (EP). Its Human Pharmacogenetic Assays include Hypercoagulation (FV, FII, MTHFR Panel) and CYP2C19 Genetic Variance. It is focused on the infectious disease diagnostics market.

Receive News & Ratings for Nanosphere Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanosphere and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit